Collectively, existing literature suggests that novel approaches targeting CCN1 expression or secretion may hold therapeutic potential for treating atherosclerosis by attenuating endothelial dysfunction, foam cell formation, and hepatic lipid accumulation. This evidence concerns the gene CCN1 and atherosclerosis.